Encouraging advances in therapies for Leber congenital amaurosis

by DBGen Ocular Genomics

Editas Medicine, a company specialising in the development of gene editing therapies, has announced the recruitment of paediatric patients to the Brilliance trial.

Read more

First CRISPR gene editing therapy for inherited visual disorders

by DBGen Ocular Genomics

On the 30th November EDIT-101, developed by Editas Medicine, received the approval from the Food and Drug Administration (FDA) to be the first in vivo CRISPR medicine administered to people anywhere i...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Iron deficiency is associated with large...

by Vall d’Hebron

The study shows that not only excess but also iron deficiency can have...

Photos Stream